TransEnterix, Inc. (TRXDW)
TransEnterix, Inc. operates in the Medical - Specialties industry of the Healthcare sector, headquartered in US. The stock last traded at $0.15, down 11.76% on the session, giving a market capitalisation of $40.1M. On trailing twelve-month figures it carries a trailing P/E of -0.48, a net margin of -914.5%. Its beta of 1.41 implies it has historically moved more than the broad market.
Asensus Surgical, Inc. is a medical technology firm dedicated to the innovation, development, and commercialization of robotic surgical systems aimed at enhancing minimally invasive procedures. The company’s global reach extends across the United States, Europe, the Middle East, Africa, and Asia. It distinguishes itself by digitizing the crucial interface between the surgeon and the patient, enabling a form of "performance-guided surgery" designed to optimize patient outcomes. The company’s product portfolio includes the Senhance System, a sophisticated multi-port robotic platform allowing surgeons to control up to four robotic arms, instruments, and a camera for laparoscopic operations. It also offers a range of specialized surgical instruments, such as 3mm diameter instruments, 3mm and 5mm hooks, and articulating tools. Furthermore, the Senhance ultrasonic system provides an advanced energy solution for the controlled ligation and division of tissue. Originally known as TransEnterix, Inc., the company officially changed its name to Asensus Surgical, Inc. in February 2021. Its corporate headquarters are located in Durham, North Carolina.
TransEnterix, Inc. is most often compared with the following Healthcare names: